Skip to main content
Caplight Logo









Hemideina

Hemideina

Private
MelbourneHealthcare & Life Scienceshttps://hemideina.com

Last Round

Series A

Oct 20, 2021

Total Funding Raised

$10.86M

Company Overview

Hemideina operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Series A round in October 2021.

Hemideina is a medical technology company that develops cochlear implant solutions for the treatment of severe-to-profound hearing loss.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Hemideina Comparables

Compare Hemideina with similar companies based on industry and business-model similarity.

Hemideina comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neubio
81%
MED-EL
79%
Envoy Medical, Inc.
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Hemideina Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 20, 2021
Series A ExtensionNov 22, 2019
Series AFeb 20, 2019
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Hemideina Investors

Notable investors and investment history

Hemideina investors
InvestorRounds
Geoni CapitalSeries A
Escala PartnersSeries A
InterValley VenturesSeries A
HenslowSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 22, 2019

    $3M round led by Henslow

  • Feb 20, 2019

    $715K round led by Chatsworth Associates.

Book a demo to see all signals

For institutional investors. Book with your work email.

Hemideina Filings

Explore SEC and related filing metadata, where available.

Hemideina filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Hemideina's valuation, stock price, and market status.

Is Hemideina a public or private company?

Hemideina is a private company.

What is the current stock price of Hemideina?

Hemideina is a private company, so its shares have no public market price. Caplight tracks Hemideina's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Hemideina worth (valuation)?

Valuation information for Hemideina is not publicly available.

Can I buy Hemideina stock?

Hemideina shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Hemideina's last funding round?

Hemideina's most recent funding round was Series A on October 20, 2021.

Who are the main investors in Hemideina?

Key investors in Hemideina include Henslow.

Will Hemideina IPO soon?

No public IPO plans have been announced for Hemideina.

How can I track Hemideina secondary market activity?

Caplight tracks bids, offers, and trades in Hemideina's shares on secondary markets.

Firmographic Details

HeadquartersMelbourne
Year Founded2017
Last FundingOct 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?